Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 1998

View Archived Issues

CV Therapeutics seeks permission to move CVT-510 to clinical trials

LeuTech completes phase I

MedImmune and SmithKline Beecham finalize vaccine agreement

AxyS launches technologies division

Inhale and Lilly to codevelop pulmonary delivery formulation

Optex awarded Phase II SBIR grant

Novel semisynthetic macrolides prepared at Abbott

Lexicon and ZymoGenetics sign functional genomics agreement

Lilly acquires rights to Sibia's drug discovery technology

Lilly discloses new agents for influenza

MS&D reveals new class of antimigraine agents

VEGF and FGF receptor TK inhibitors from Zeneca

SmithKline Beecham develops Lp-PLA2 inhibitors for atherosclerosis

Novel atypical antipsychotic agent presented by Lundbeck

Novel gene therapy for chemoprotection of bone marrow found safe in early clinical trials

New HIV vaccine from VaxGen cleared for phase I/II studies

Lovenox/Clexane receives approvals in 11 additional countries

Zeneca commits to development of Zomig line extensions

Sheffield proceeds with development of respiratory drugs in its MSI

Preclinical efficacy results reported for Maruho's NSAID

CVT-313: promising antiproliferative agent that inhibits CDK2

Filgrastim reduces neutropenia and morbidity associated with AML treatment

Pharmacopeia achieves milestone in collaboration with Daiichi

BioTime lays groundwork for Japanese licensing of Hextend

Controlled-release tramadol under development

IL-12 offers new approach to BMT in leukemia patients

Ribozyme, Parke-Davis intend to collaborate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...